Drug Trial Radar · NCT04777357
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
338
Planned (sponsor's estimate)
Start
Apr 28, 2021
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population. Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 338 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites in the US and Puerto Rico. Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Depression
- Bipolar I Disorder
Interventions
CariprazineDrug
Oral Capsule
PlaceboDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Baseline (Week 0) to Week 10
- Abnormal Change from Baseline in Vital SignsTime frame: Baseline (Week 0) to Week 10
- Number of Participants with Incidence of Abnormal Clinical Laboratory Test ResultsTime frame: Baseline (Week 0) to Week 6
- Change in Electrocardiogram (ECG)Time frame: Baseline (Week 0) to Week 6
- Change From Baseline in Simpson-Angus Scale (SAS)Time frame: Baseline (Week 0) to Week 6
- Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline (Week 0) to Week 10
- Change From Baseline in Barnes Akathisia Rating Scale (BARS)Time frame: Baseline (Week 0) to Week 6
- Change From Baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Baseline (Week 0) to Week 6
- Change in Children's Depression Rating Scale - Revised (CDRS-R) Total ScoreTime frame: Baseline (Week 0) to Week 6
Locations
87 sites in 3 countries. Site status is shown where the registry gives one.
Pillar Clinical Research /ID# 226504
Bentonville, Arkansas · Completed
Advanced Research Center /ID# 227073
Anaheim, California · Recruiting
Care Access Research /ID# 226316
Beverly Hills, California · Completed
Inland Pyschiatric Medical Group - Chino /ID# 278667
Chino, California · Recruiting
ProScience Research Group /ID# 226223
Culver City, California · Completed
National Institute of Clinical Research - Garden Grove /ID# 262835
Garden Grove, California · Completed
Accellacare - Long Beach /ID# 279482
Long Beach, California · Recruiting
Duplicate_Alliance for Research - Long Beach /ID# 226522
Long Beach, California · Completed
Atp Clinical Research - Orange /ID# 253719
Orange, California · Completed
CHOC Children's Hospital /ID# 260298
Orange, California · Recruiting
Prospective Research Innovations Inc /ID# 240774
Rancho Cucamonga, California · Completed
Inland Psychiatric Medical Group /ID# 274621
Redlands, California · Recruiting
University of California Davis Health /ID# 268306
Sacramento, California · Recruiting
University of California, San Diego Department of Psychiatry /ID# 226463
San Diego, California · Completed
Lumos Clinical Research Center /ID# 262805
San Jose, California · Completed
Pacific Clinical Research Management Group /ID# 227075
Upland, California · Completed
Kinetic Clinical Research /ID# 277152
West Covina, California · Recruiting
D&H Doral Research Center-Doral /ID# 255458
Doral, Florida · Recruiting
Advanced Research Institute of Miami /ID# 228222
Homestead, Florida · Completed
Innovus Clinical Research /ID# 282255
Kissimmee, Florida · Recruiting
Columbus Clinical Services, Llc /Id# 229792
Miami, Florida · Completed
G+C Research Group, LLC /ID# 261399
Miami, Florida · Completed
Florida Research Center, Inc. /ID# 240775
Miami, Florida · Recruiting
South Florida Research Ph I-IV /ID# 240778
Miami Springs, Florida · Completed
Medical Research Group of Central Florida /ID# 256757
Orange City, Florida · Completed
APG Research, LLC /ID# 226519
Orlando, Florida · Completed
Nova Psychiatry Inc. /ID# 270892
Orlando, Florida · Completed
Panhandle Research and Medical Clinic, LLC /ID# 268522
Pensacola, Florida · Completed
D&H Tamarac Research Center /ID# 250434
Tamarac, Florida · Recruiting
University of South Florida- Neuroscience Institute /ID# 246508
Tampa, Florida · Completed
Atlanta Center for Medical Research /ID# 226480
Atlanta, Georgia · Completed
CenExcel iResearch LLC /ID# 228695
Decatur, Georgia · Completed
Atlanta Behavioral Research, LLC /ID# 226486
Dunwoody, Georgia · Completed
Sleep Care Research Institute d/b/a Clinical Research Institute /ID# 226371
Stockbridge, Georgia · Completed
Denali Health Atlanta, LLC /ID# 278167
Stone Mountain, Georgia · Recruiting
Duplicate_Ascension St. Elizabeth /ID# 240772
Chicago, Illinois · Completed
Baber Research Group /ID# 232279
Naperville, Illinois · Completed
Advanced Quality Medical Research /ID# 272902
Orland Park, Illinois · Recruiting
Indiana University /ID# 260705
Indianapolis, Indiana · Completed
Benchmark Research /ID# 260714
Shreveport, Louisiana · Completed
Showing 40 of 87 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.